NCT04745689Active, not recruitingPhase 2
Study of AZD2811 + Durvalumab in ES-SCLC
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction With Platinum-Based Chemotherapy Combined With Durvalumab, for the First-Line Treatment of Patients With Extensive Stage Small-Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 6 Jul 2026
Brief summary (registry, in English)
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- First submitted
- 16 Dec 2020
- Start date
- 23 Feb 2021
- Primary completion date
- 18 Jun 2022
- Lead sponsor
- AstraZeneca
- Diseases
- Lung cancer
- NCT number
- NCT04745689
- EU CT number
- 2024-511887-10-00
- EudraCT number
- 2020-004091-18
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 31
- From 23 Feb 2021 to the primary completion date, 18 Jun 2022
- 8 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy
- Active or prior documented autoimmune or inflammatory disorders
Other illness
- Has a paraneoplastic syndrome (PNS) of autoimmune nature, requiring systemic treatment (systemic steroids or immunosuppressive agents) or has a clinical symptomatology suggesting worsening of PNS
- Active infection including tuberculosis, HIV, hepatitis B and C
- Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.
Who the study is looking for
- Documented evidence of extensive stage SCLC (ES-SCLC)
- Participants must be considered suitable to receive an induction platinum-based chemotherapy regimen, combined with durvalumab, as first-line treatment for ES-SCLC
- No prior exposure to immune-mediated therapy
- Life expectancy ≥12 weeks at Day 1.
- ECOG 0 or 1 at enrolment.
Age in the registry: 18 years to 130 years · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Arnau de Vilanova de Valencia Coordinator of this site? Confirm its status | Valencia | Spain | Active, not recruiting |
| Research Site Coordinator of this site? Confirm its status | Cheongju-si | South Korea | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Jinju | South Korea | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Bydgoszcz | Poland | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Olsztyn | Poland | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Poznan | Poland | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Grand Rapids | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.